article · Open Forum Infectious Diseases
A retrospective study in Nigeria examined the long-term outcomes of Dolutegravir-based antiretroviral therapy (TLD) in a large cohort of 33,982 people living with HIV. The research focused on individuals either starting TLD or switching to it between 2017 and 2019. Findings indicated that virological suppression, meaning the reduction of the viral load to undetectable levels, reached 80–82% among participants for whom viral load data was available. When analysed by intention-to-treat, which includes all participants regardless of data availability, the suppression rate was 63–65%. The study also observed that individuals who switched to TLD achieved higher suppression rates. Furthermore, age and gender were identified as predictive factors for achieving virological suppression.
This research provides important real-world data on the effectiveness of Dolutegravir-based HIV treatment in a large African population. Understanding suppression rates and influencing factors helps optimise treatment strategies, improving health outcomes for people living with HIV and informing public health programmes.
The abstract describes an observational study of an existing treatment regimen. It does not indicate an application pathway for new products or services, nor does it suggest a direct commercialisation opportunity.
AI-generated from the published abstract. Always read the original work before citing.
Abstract In a retrospective Nigerian cohort of 33,982 PLHIV initiating or switching to TLD, virological suppression reached 80–82% among participants with available viral load data and 63–65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1093/ofid/ofag549
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
